This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Moderna (MRNA) and Ionis Pharmaceuticals (IONS)

Tipranks - Tipranks - Fri Jun 12, 5:48AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Madrigal Pharmaceuticals (MDGL), Moderna (MRNA) and Ionis Pharmaceuticals (IONS).

Introducing TipRanks MCP for Agents

Madrigal Pharmaceuticals (MDGL)

In a report released today, Jason Zemansky from Bank of America Securities reiterated a Hold rating on Madrigal Pharmaceuticals, with a price target of $542.00. The company’s shares closed last Wednesday at $471.32.

According to TipRanks.com, Zemansky is a 5-star analyst with an average return of 14.8% and a 49.4% success rate. Zemansky covers the Healthcare sector, focusing on stocks such as Inhibikase Therapeutics, Acumen Pharmaceuticals, and Rocket Pharmaceuticals. ;'>

Currently, the analyst consensus on Madrigal Pharmaceuticals is a Strong Buy with an average price target of $648.82.

See the top stocks recommended by analysts >>

Moderna (MRNA)

In a report released today, Alec Stranahan from Bank of America Securities maintained a Sell rating on Moderna, with a price target of $34.00. The company’s shares closed last Wednesday at $45.99, close to its 52-week low of $29.25.

According to TipRanks.com, Stranahan is a 4-star analyst with an average return of 3.6% and a 45.6% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, Perspective Therapeutics, and Crispr Therapeutics AG. ;'>

Currently, the analyst consensus on Moderna is a Hold with an average price target of $44.76.

Ionis Pharmaceuticals (IONS)

Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Ionis Pharmaceuticals today and set a price target of $111.00. The company’s shares closed last Wednesday at $73.32.

According to TipRanks.com, Gerberry is a 5-star analyst with an average return of 18.4% and a 59.0% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., Arrowhead Pharmaceuticals, and BioMarin Pharmaceutical. ;'>

Ionis Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $107.06, a 43.8% upside from current levels. In a report issued on May 29, TipRanks – Google also upgraded the stock to Buy with a $85.00 price target.

Read More on MDGL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).